Abstract: Embodiments of a composition comprising three or four Bacillus species selected from Bacillus amyloliquefaciens, Bacillus subtilis, Bacillus licheniformis and Bacillus coagulans are disclosed. The composition may further comprise, or be used in combination with, feed and/or feed supplements, including feed supplements comprising Yucca, Quillaja, silica, mineral clay, glucan, mannans, or combinations thereof. Also disclosed is a method of administering the composition and/or combination to animals, such as poultry.
Abstract: The present invention is directed to a composition comprising at least one fibronectin binding polypeptide (FnBP) linked to at least one diagnostic or therapeutic agent, a nucleic acid encoding a fusion polypeptide comprising at least one fibronectin binding polypeptide (FnBP) linked to at least one diagnostic or therapeutic polypeptide agent as well as a corresponding recombinant vector and host cell comprising such a nucleic acid and preferably expressing said fusion polypeptide. The invention also relates to a kit of parts comprising at least one fibronectin binding polypeptide (FnBP), at least one diagnostic or therapeutic agent, and optionally one or more chemical agents for linking the fibronectin binding polypeptide (FnBP) to the diagnostic or therapeutic agent.
Type:
Grant
Filed:
June 14, 2017
Date of Patent:
May 16, 2023
Assignees:
ETH ZURICH, PAUL SCHERRER INSTITUT
Inventors:
Mamta Chabria, Alessandra Moscaroli, Simon Arnoldini, Samuel Hertig, Viola Vogel, Martin Behe, Roger Schibli
Abstract: The present disclosure relates to compositions and methods for inducing an immune response to a composition of the invention in a subject. Additionally, the present disclosure generally relates to methods for screening for immune response to a composition of the invention.
Type:
Grant
Filed:
June 19, 2018
Date of Patent:
May 9, 2023
Assignees:
Washington University, BLUEWILLOW BIOLOGICS
Inventors:
Shabaana Abdul Khader, Mushtaq Ahmed, Ali Fattom, Douglas Smith, Tarek Hamouda
Abstract: The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.
Type:
Grant
Filed:
April 25, 2022
Date of Patent:
May 9, 2023
Assignee:
SNIPR Biome ApS
Inventors:
Morten Sommer, Virginia Martinez, Eric Van Der Helm, Jakob Krause Haaber, Ana De Santiago Torio, Christian Grøndahl, Jasper Clube
Abstract: Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.
Type:
Grant
Filed:
December 14, 2020
Date of Patent:
April 25, 2023
Assignees:
University of Washington, The UAB Research Foundation
Inventors:
Jens H. Gundlach, Michael Niederweis, Thomas Z. Butler, Mikhail Pavlenok, Mark A. Troll, Suja Sukumaran
Abstract: Bacterial strains are provided having at least one of a reduced size, a sialic acid coat, inducibly altered surface antigens, and expression of PD-L1 or CTLA-4 antagonists and/or tryptophanase. The bacteria may have improved serum half-life, increased penetration into tumors, increased tumor targeting and increased antitumor activity. The bacteria are useful for delivery of therapeutic agents that treat of neoplastic diseases including solid tumors and lymphomas.
Abstract: Pharmaceutical compositions containing microbial entities are described herein. The pharmaceutical compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the pharmaceutical compositions to treat or prevent disorders of the local or systemic microbiome in a subject are also provided.
Type:
Grant
Filed:
August 23, 2019
Date of Patent:
March 21, 2023
Assignee:
Evelo Biosciences, Inc.
Inventors:
David Berry, Johanne Kaplan, Shaila Rahman
Abstract: Disclosed are P. gingivalis antibodies raised against a chimeric or fusion protein, wherein the chimeric or fusion protein comprises a first peptide joined directly or through a linker to a second peptide or polypeptide, wherein (A) the first peptide comprises a region of a P. gingivalis trypsin-like enzyme and (B) the second peptide or polypeptide comprises an adhesin domain of P. gingivalis.
Type:
Grant
Filed:
November 13, 2020
Date of Patent:
February 7, 2023
Assignee:
Oral Health Australia PTY Ltd
Inventors:
Eric Charles Reynolds, Neil Martin O'Brien Simpson, Keith J. Cross, Nada Slakeski
Abstract: A method of inhibiting growth of a bacterium including steps of: a) delivering a polynucleotide including a sequence of SEQ ID NO: 1 or a homologue thereof to the bacterium, and b) contacting the bacterium with an effective amount of an antibiotic; wherein the bacterium is Pseudomonas aeruginosa. A method of treating a subject suffering from an infection caused by a bacterium which is Pseudomonas aeruginosa and the method including steps of: i) delivering said polynucleotide to a tissue infected by the bacterium or a bacterial cell in the subject; and ii) administering an effective amount of an antibiotic to the subject. A composition and a recombinant plasmid containing said polynucleotide.
Abstract: This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.
Type:
Grant
Filed:
May 20, 2014
Date of Patent:
December 13, 2022
Assignee:
Zoetis Services LLC
Inventors:
Cassius McAllister Tucker, John David Haworth
Abstract: This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.
Type:
Grant
Filed:
June 24, 2020
Date of Patent:
December 13, 2022
Assignee:
Zoetis Services LLC
Inventors:
Cassius McAllister Tucker, John David Haworth
Abstract: Protein complex variants, compositions, and methods of use thereof are provided. The protein complex variant includes a cholera toxin B subunit variant having one or more modifications thereto. The method of use thereof includes treating a disease by administering an effective amount of a composition including a cholera toxin B subunit variant to a subject in need thereof.
Type:
Grant
Filed:
August 19, 2020
Date of Patent:
December 13, 2022
Assignee:
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
Inventors:
Nobuyuki Matoba, Keegan Baldauf, Joshua Royal
Abstract: Aspects of the disclosure relate to methods and compositions useful for in vivo and/or in vitro enzyme profiling. In some embodiments, the disclosure provides methods of in vivo enzymatic processing of exogenous molecules followed by detection of signature molecules as representative of the presence of active enzymes associated with diseases or conditions. In some embodiments, the disclosure provides compositions and in vitro methods for localization of enzymatic activity in a tissue sample.
Type:
Grant
Filed:
April 6, 2018
Date of Patent:
December 6, 2022
Assignee:
Massachusetts Institute of Technology
Inventors:
Sangeeta N. Bhatia, Jaideep S. Dudani, Ester J. Kwon, Andrew David Warren
Abstract: A diagnostically useful carrier includes (a) a peptide including the amino acid sequence set forth in SEQ ID NO:1 or a variant thereof, and (b) a somatic lysate of Toxocara canis larvae. Further, a kit, use, methods, and compositions that include the diagnostically useful carrier are disclosed.
Type:
Grant
Filed:
June 30, 2020
Date of Patent:
December 6, 2022
Assignee:
EUROIMMUN Medizinische Labordiagnostika AG
Inventors:
Babett Menge, Katja Steinhagen, Juliane Schaefer, Christian Probst, Andrea Deerberg, Mandy Unger, Claudia Messing
Abstract: The present invention relates to recombinant virulence attenuated Gram-negative bacterial strains and its use in a method of treating cancer in a subject.
Type:
Grant
Filed:
December 20, 2017
Date of Patent:
December 6, 2022
Assignee:
Universitaet Basel
Inventors:
Simon Ittig, Marlise Amstutz, Christoph Kasper
Abstract: Disclosed are an immunochemical assay device and a method of using the immunochemical assay device for detecting one or more targets or markers such as Cardiac Troponin I, NT-pro-BNP, D-dimer and/or cross-linked fibrin in a fluid sample.
Abstract: A composition contains at least one probiotic or enzyme selected from the group consisting of (i) a probiotic having ?-glycosidase activity or a ?-glycosidase, (ii) a probiotic having esterase activity or an esterase, (iii) a probiotic having both ?-glycosidase activity and esterase activity or an enzyme having both ?-glycosidase activity and esterase activity, (iv) a first probiotic having ?-glycosidase activity and a second probiotic having esterase activity, (v) a probiotic having ?-glycosidase activity and an esterase, (vi) a ?-glycosidase and a probiotic having esterase activity and (vii) a ?-glycosidase and an esterase. The at least one probiotic can form one or more of oleuropein aglycone, elenolic acid, hydroxytyrosol acetate or hydroxytyrosol from oleuropein. The composition can comprise oleuropein.
Type:
Grant
Filed:
November 8, 2018
Date of Patent:
November 22, 2022
Assignee:
Societe des Produits Nestle S.A.
Inventors:
Marie Noelle Horcajada, Stephane Duboux, Laure Poquet
Abstract: A composition for treating or preventing COVID-19 infection is described. The composition includes attenuated Measles virus particles; attenuated Mumps virus particles; attenuated Rubella II virus particles; scorpion antivenom; and a pharmaceutically acceptable carrier. The composition can be used in a method of treating COVID-19 infection in a subject, and can also be used in a method of vaccinating a subject to decrease the risk or severity of infection by COVID-19.
Abstract: The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.
Type:
Grant
Filed:
September 23, 2020
Date of Patent:
November 1, 2022
Assignee:
SNIPR Biome ApS
Inventors:
Morten Sommer, Virginia Martinez, Eric Van der Helm, Jakob Krause Haaber, Ana De Santiago Torio, Christian Grøndahl, Jasper Clube
Abstract: Provided herein are genetically engineered Vibrio cholerae bacterial strains, compositions including the bacterial strains, and methods of using the same for the prevention of Vibrio cholerae infection in a subject.
Type:
Grant
Filed:
July 12, 2018
Date of Patent:
November 1, 2022
Assignee:
The Brigham and Women's Hospital, Inc.
Inventors:
Matthew K. Waldor, Troy Hubbard, Gabriel Billings